跳至主要内容
临床试验/NCT01850797
NCT01850797已完成不适用

Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)

University Hospital Heidelberg1 个研究点 分布在 1 个国家目标入组 353 人开始时间: 2012年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
353
试验地点
1
主要终点
Rate of hematoma expansion (ICH)

研究概览

简要总结

The registry of acute stroke under new oral anticoagulants (RASUNOA) is a German multicenter, prospective, observational registry performed at about 50 study centers covering about 50.000 acute ischemic strokes and 6000 acute intracranial hemorrhages per year. Study enrollment will be consecutive. The RASUNOA registry study center is the University Medical Center of the Principal Investigator (Heidelberg, Germany). The registry will focus on treatment decisions and concepts in patients being under treatment with a new oral anticoagulant and suffering from acute ischemic or hemorrhagic stroke.

详细描述

The main purpose of the study is to collect information from a large, prospectively enrolling multicentre stroke database regarding the optimal management of ischemic and hemorrhagic stroke during anticoagulation with nOAC. Specifically, we aim to obtain critical information regarding the epidemiology, natural history, laboratory and neuroradiological aspects, clinical consequences, and the effects of treatment (i.e. thrombolysis/interventional recanalisation in ischemic stroke and hemostatic therapy in ICH, respectively) in stroke during nOAC. The Registry is not limited to a specific new OAC but intends to examine stroke during use of any of the approved nOAC. The study is not designed to perform comparisons among the different nOAC.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age >= 18 years
  • informed consent
  • acute stroke or intracranial bleeding
  • therapy with a new oral anticoagulant (Dabigatran®, Rivaroxaban®, Apixaban®, Edoxaban®)

排除标准

  • missing informed consent

结局指标

主要结局

Rate of hematoma expansion (ICH)

时间窗: 48h after ICH

Rate of hematoma enlargement in patients with ICH between initial imaging and follow-up imaging (CT)

Symptomatic intracerebral haemorrhage after thrombolysis

时间窗: 24 h

In patients with ischemic stroke while under treatment with any of the new OAC who receive thrombolysis we will measure any hemorrhagic transformation on routine follow-up CT imaging (usually within 24h after thrombolysis)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof. Roland Veltkamp

Senior Physician, Department of Neurology, University Hospital Heidelberg

University Hospital Heidelberg

研究点 (1)

Loading locations...

相似试验

Registry of Acute Stroke Under New Oral... | 临床试验